Vascular KCNQ (Kv7) potassium channels as common signaling intermediates and therapeutic targets in cerebral vasospasm

Journal of Cardiovascular Pharmacology

Volumn 61, Issue 1, 2013, Pages 51-62

  Mani, Bharath K ^a   O'Dowd, James ^a   Kumar, Lalit ^a   Brueggemann, Lioubov I ^a   Ross, Masey ^a   Byron, Kenneth L ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

basilar artery; celecoxib; cerebral vasospasm; membrane depolarization; potassium channel; retigabine

Indexed keywords

BUPRENORPHINE; CALCIUM CHANNEL; CELECOXIB; ENDOTHELIN; POTASSIUM CHANNEL KCNQ; RETIGABINE; SEROTONIN; VASOPRESSIN;

ANALGESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL PRESSURE; ARTICLE; BASILAR ARTERY; BRAIN VASOSPASM; CONTROLLED STUDY; DEPOLARIZATION; MUSCLE CELL; MYOGRAPHY; NONHUMAN; PATCH CLAMP; PRESSURE MYOGRAPHY; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; SLOW INWARD CURRENT; SUBARACHNOID HEMORRHAGE; VASOCONSTRICTION;

ANIMALS; ANTHRACENES; ARGININE VASOPRESSIN; BASILAR ARTERY; CARBAMATES; DISEASE MODELS, ANIMAL; ENDOTHELIN-1; KCNQ POTASSIUM CHANNELS; MALE; MEMBRANE TRANSPORT MODULATORS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; MYOGRAPHY; PATCH-CLAMP TECHNIQUES; PHENYLENEDIAMINES; POTASSIUM CHANNEL BLOCKERS; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; SIGNAL TRANSDUCTION; SUBARACHNOID HEMORRHAGE; SULFONAMIDES; TIME FACTORS; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS; VASOSPASM, INTRACRANIAL;

EID: 84872356745     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3182771708     Document Type: Article

References (54)

1. Kassell NF, Sasaki T, Colohan AR, et al. Cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Stroke. 1985;16:562-572.
2. Crowley RW, Medel R, Kassell NF, et al. New insights into the causes and therapy of cerebral vasospasm following subarachnoid hemorrhage. Drug Discov Today. 2008;13:254-260.
3. Clark JF, Sharp FR. Bilirubin oxidation products (BOXes) and their role in cerebral vasospasm after subarachnoid hemorrhage. J Cereb Blood Flow Metab. 2006;26:1223-1233.
4. Kozniewska E, Michalik R, Rafalowska J, et al. Mechanisms of vascular dysfunction after subarachnoid hemorrhage. J Physiol Pharmacol. 2006; 57(suppl 11):145-160.
5. Kolias AG, Sen J, Belli A. Pathogenesis of cerebral vasospasm following aneurysmal subarachnoid hemorrhage: putative mechanisms and novel approaches. J Neurosci Res. 2009;87:1-11.
6. Rothoerl RD, Ringel F. Molecular mechanisms of cerebral vasospasm following aneurysmal SAH. Neurol Res. 2007;29:636-642.
7. Macdonald RL, Weir BK. A review of hemoglobin and the pathogenesis of cerebral vasospasm. Stroke. 1991;22:971-982.
8. Harder DR, Dernbach P, Waters A. Possible cellular mechanism for cerebral vasospasm after experimental subarachnoid hemorrhage in the dog. J Clin Invest. 1987;80:875-880.
9. Jahromi BS, Aihara Y, Ai J, et al. Voltage-gated K+ channel dysfunction in myocytes from a dog model of subarachnoid hemorrhage. J Cereb Blood Flow Metab. 2008;28:797-811.
10. Nystoriak MA, O'Connor KP, Sonkusare SK, et al. Fundamental increase in pressure-dependent constriction of brain parenchymal arterioles from subarachnoid hemorrhage model rats due to membrane depolarization. Am J Physiol Heart Circ Physiol. 2010;300:H803-H812.
11. Wellman GC. Ion channels and calcium signaling in cerebral arteries following subarachnoid hemorrhage. Neurol Res. 2006;28:690-702.
12. Bederson JB, Connolly ES Jr, Batjer HH, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke. 2009;40:994-1025.
13. Porchet F, Chiolero R, de Tribolet N. Hypotensive effect of nimodipine during treatment for aneurysmal subarachnoid haemorrhage. Acta Neurochir (Wien). 1995;137:62-69.
14. Dorhout Mees SM, Rinkel GJ, Feigin VL, et al. Calcium antagonists for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev. 2007;18:CD000277.
15. Nelson MT, Quayle JM. Physiological roles and properties of potassium channels in arterial smooth muscle. Am J Physiol. 1995;268(4 pt 1):C799-C822.
16. Wulff H, Castle NA, Pardo LA. Voltage-gated potassium channels as therapeutic targets. Nat Rev Drug Discov. 2009;8:982-1001.
17. Joshi S, Sedivy V, Hodyc D, et al. KCNQ modulators reveal a key role for KCNQ potassium channels in regulating the tone of rat pulmonary artery smooth muscle. J Pharmacol Exp Ther. 2009;329:368-376.
18. Yeung SY, Pucovsky V, Moffatt JD, et al. Molecular expression and pharmacological identification of a role for K(v)7 channels in murine vascular reactivity. Br J Pharmacol. 2007;151:758-770.
19. Mackie AR, Brueggemann LI, Henderson KK, et al. Vascular KCNQ potassium channels as novel targets for the control of mesenteric artery constriction by vasopressin, based on studies in single cells, pressurized arteries, and in vivo measurements of mesenteric vascular resistance. J Pharmacol Exp Ther. 2008;325:475-483.
20. Mani BK, Brueggemann LI, Cribbs LL, et al. Activation of vascular KCNQ (Kv7) potassium channels reverses spasmogen-induced constrictor responses in rat basilar artery. Br J Pharmacol. 2011;164:237-249.
21. Zhong XZ, Harhun MI, Olesen SP, et al. Participation of KCNQ (Kv7) potassium channels in myogenic control of cerebral arterial diameter. J Physiol. 2010;588(pt 17):3277-3293.
22. Brueggemann LI, Mackie AR, Mani BK, et al. Differential effects of selective cyclooxygenase-2 inhibitors on vascular smooth muscle ion channels may account for differences in cardiovascular risk profiles. Mol Pharmacol. 2009;76:1053-1061.
23. Brueggemann LI, Kakad PP, Love RB, et al. Kv7 potassium channels in airway smooth muscle cells: signal transduction intermediates and pharmacological targets for bronchodilator therapy. Am J Physiol Lung Cell Mol Physiol. 2012;302:L120-L132.
24. Gules I, Satoh M, Clower BR, et al. Comparison of three rat models of cerebral vasospasm. Am J Physiol Heart Circ Physiol. 2002;283: H2551-H2559.
25. Cuzzocrea S, Mazzon E, Sautebin L, et al. Protective effects of Celecoxib on lung injury and red blood cells modification induced by carrageenan in the rat. Biochem Pharmacol. 2002;63:785-795.
26. Blackburn-Munro G, Dalby-Brown W, Mirza NR, et al. Retigabine: chemical synthesis to clinical application. CNS Drug Rev. 2005;11:1-20.
27. Murray MA, Faraci FM, Heistad DD. Effect of protein kinase C inhibitors on endothelin-and vasopressin-induced constriction of the rat basilar artery. Am J Physiol. 1992;263(6 pt 2):H1643-H1649.
28. Murray MA, Faraci FM, Heistad DD. Role of protein kinase C in constrictor responses of the rat basilar artery in vivo. J Physiol. 1992;445: 169-179.
29. Albert AP, Large WA. Signal transduction pathways and gating mechanisms of native TRP-like cation channels in vascular myocytes. J Physiol. 2006;570(pt 1):45-51.
30. Laher I, Zhang JH. Protein kinase C and cerebral vasospasm. J Cereb Blood Flow Metab. 2001;21:887-906.
31. Nelson MT, Quayle JM. Physiological roles and properties of potassium channels in arterial smooth muscle. Am J Physiol Cell Physiol. 1995;268: C799-C822.
32. Cole WC, Clement-Chomienne O, Aiello EA. Regulation of 4-aminopyridinesensitive, delayed rectifier K+ channels in vascular smooth muscle by phosphorylation. Biochem Cell Biol. 1996;74:439-447.
33. Knot HJ, Nelson MT. Regulation of membrane potential and diameter by voltage-dependent K+ channels in rabbit myogenic cerebral arteries. Am J Physiol Heart Circ Physiol. 1995;269(1 pt 2):H348-H355.
34. Doggrell SA, Wanstall JC, Gambino A. Functional effects of 4-aminopyridine (4-AP) on pulmonary and systemic vessels from normoxic control and hypoxic pulmonary hypertensive rats. Naunyn Schmiedebergs Arch Pharmacol. 1999;360:317-323.
35. Horiuchi T, Dietrich HH, Tsugane S, et al. Role of potassium channels in regulation of brain arteriolar tone. Stroke. 2001;32:218-224.
36. Firth AL, Remillard CV, Platoshyn O, et al. Functional ion channels in human pulmonary artery smooth muscle cells: voltage-dependent cation channels. Pulm Circ. 2011;1:48-71.
37. Cogolludo A, Moreno L, Lodi F, et al. Serotonin inhibits voltage-gated K+ currents in pulmonary artery smooth muscle cells. Circ Res. 2006;98: 931-938.
38. Jeon H, Ai J, Sabri M, et al. Neurological and neurobehavioral assessment of experimental subarachnoid hemorrhage. BMC Neurosci. 2009; 10:103.
39. Nagao S, Irie K, Kawai N, et al. The use of mild hypothermia for patients with severe vasospasm: a preliminary report. J Clin Neurosci. 2003;10: 208-212.
40. Torok E, Klopotowski M, Trabold R, et al. Mild hypothermia (33 degrees C) reduces intracranial hypertension and improves functional outcome after subarachnoid hemorrhage in rats. Neurosurg. 2009;65: 352-359.
41. Boscia F, Annunziato L, Taglialatela M. Retigabine and flupirtine exert neuroprotective actions in organotypic hippocampal cultures. Neuropharm. 2006;51:283-294.
42. Seyfried J, Evert BO, Rundfeldt C, et al. Flupirtine and retigabine prevent L-glutamate toxicity in rat pheochromocytoma PC 12 cells. Eur J Pharmacol. 2000;400:155-166.
43. Gamper N, Zaika O, Li Y, et al. Oxidative modification of M-type K+ channels as a mechanism of cytoprotective neuronal silencing. EMBO J. 2006;25:4996-5004.
44. Nodera H, Spieker A, Sung M, et al. Neuroprotective effects of Kv7 channel agonist, retigabine, for cisplatin-induced peripheral neuropathy. Neurosci Lett. 2011;505:223-227.
45. Ayer R, Jadhav V, Sugawara T, et al. The neuroprotective effects of cyclooxygenase-2 inhibition in a mouse model of aneurysmal subarachnoid hemorrhage. Acta Neurochir Suppl. 2011;111:145-149.
46. Osuka K, Watanabe Y, Yamauchi K, et al. Activation of the JAK-STAT signaling pathway in the rat basilar artery after subarachnoid hemorrhage. Brain Res. 2006;1072:1-7.
47. Tran Dinh YR, Jomaa A, Callebert J, et al. Overexpression of cyclooxygenase-2 in rabbit basilar artery endothelial cells after subarachnoid hemorrhage. Neurosurgery. 2001;48:626-633.
48. Ishiguro M, Morielli AD, Zvarova K, et al. Oxyhemoglobin-induced suppression of voltage-dependent K+ channels in cerebral arteries by enhanced tyrosine kinase activity. Circ Res. 2006;99:1252-1260.
49. Hou S, Xu R, Clark JF, et al. Bilirubin oxidation end products directly alter K+ channels important in the regulation of vascular tone. J Cereb Blood Flow Metab. 2011;31:102-112.
50. Kwan AL, Lin CL, Yanamoto H, et al. Systemic administration of the potassium channel activator cromakalim attenuates cerebral vasospasm after experimental subarachnoid hemorrhage. Neurosurgery. 1998;42: 347-350; discussion: 350-351.
51. Zuccarello M, Bonasso CL, Lewis AI, et al. Relaxation of subarachnoid hemorrhage-induced spasm of rabbit basilar artery by the K+ channel activator cromakalim. Stroke. 1996;27:311-316.
52. Spinelli W, Follmer C, Parsons R, et al. Effects of cromakalim, pinacidil and nicorandil on cardiac refractoriness and arterial pressure in openchest dogs. Eur J Pharmacol. 1990;179:243-252.
53. Jentsch TJ. Neuronal KCNQ potassium channels: physiology and role in disease. Nat Rev Neurosci. 2000;1:21-30.
54. Gunthorpe MJ, Large CH, Sankar R. The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy. Epilepsia. 2012;53:412-424.